<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00981747</url>
  </required_header>
  <id_info>
    <org_study_id>200906736</org_study_id>
    <nct_id>NCT00981747</nct_id>
  </id_info>
  <brief_title>Targeting Vascular Reactivity in Idiopathic Pulmonary Fibrosis</brief_title>
  <official_title>A Clinical Treatment Trial Targeting Vascular Reactivity in Idiopathic Pulmonary Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alicia Gerke</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pulmonary Fibrosis Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Iowa</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether combination therapy with sildenafil and
      losartan can improve function and exercise tolerance in patients with idiopathic pulmonary
      fibrosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is currently suspected that the fibrosis in IPF is based upon an abnormal reparative
      process in the lung. Normally, an insult to the endothelium or epithelium of the lung would
      trigger an inflammatory process to help repair the site of injury; epithelial and endothelial
      cells then replicate and repair the tissue damage. In pulmonary fibrosis, alterations in this
      cascade change the balance of the inflammatory products and reduce the regulatory response
      which can produce continued inflammation. Fibrosis results from continued deposition of
      collagen by proliferating fibroblasts and lack of collagen breakdown.

      In addition to fibrosis and microvascular destruction, pulmonary hypertension in IPF patients
      is a significant contributor to morbidity and mortality. The prevalence ranges from 32-85%,
      suggesting that pulmonary vascular disease is one of several processes that contribute to
      severity of disease.

      We propose use of two therapeutic agents that affect the balance of vasoconstriction and
      vasodilation to improve basal tone of the vasculature. First, we propose the use of a
      phosphodiesterase inhibitor. Sildenafil (Viagra, Revatio) is an orally administered
      vasodilator that prolongs the effect of nitric oxide by inhibiting phosphodiesterase type 5
      (PDE-5) which is responsible for degradation of cGMP. Increased cGMP concentration results in
      pulmonary vasculature relaxation and consequent vasodilation. Second, the use of an
      angiotensin receptor blocker (ARB) acts to diminish the direct vasoconstrictor effect of
      angiotensin and endothelin-1 in the vessels. In treatment of systemic hypertension, ARBs have
      been shown to be associated with a decrease in the amount of circulating endothelin-1 and
      increase in basal nitric oxide release. They have also been shown to rapidly inhibit the
      generation of reactive oxygen species by inflammatory cells. We test these interventions in a
      randomized cross-over trial in IPF patients.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Funding was withdrawn.
  </why_stopped>
  <start_date type="Actual">September 2009</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Participants will receive sildenafil for three months then losartan for three months, then sildenafil and losartan for three months and then placebo for three months in a random order.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Six Minute Walk Distance in Meters</measure>
    <time_frame>At baseline and three months post each intervention.</time_frame>
    <description>Change in 6MWD before and after treatment compared to placebo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Forced Vital Capacity (FVC)</measure>
    <time_frame>At baseline and three months post each intervention.</time_frame>
    <description>Change in FVC before and after treatment compared to placebo. FVC is a measure of lung size.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Shortness of Breath (SOB) Score</measure>
    <time_frame>At baseline and three months post each intervention.</time_frame>
    <description>Change in symptoms of SOB as determined by St. Georges Respiratory Questionnaire score. This score ranges from 0 to 100 with a higher score indicating more problems breathing.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Idiopathic Pulmonary Fibrosis</condition>
  <condition>Pulmonary Fibrosis</condition>
  <arm_group>
    <arm_group_label>All study participants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study participants are patients that have been diagnosed with idiopathic pulmonary fibrosis (IPF).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sildenafil</intervention_name>
    <description>Sildenafil 20mg three times per day for 3 months followed by a one month washout prior to next intervention.</description>
    <arm_group_label>All study participants</arm_group_label>
    <other_name>Viagra</other_name>
    <other_name>Revatio</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Losartan</intervention_name>
    <description>Losartan 25mg two times a day for 3 months followed by a one month washout prior to next intervention.</description>
    <arm_group_label>All study participants</arm_group_label>
    <other_name>Cozaar: losartan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sildenafil and Losartan</intervention_name>
    <description>Sildenafil 20mg three times per day and Losartan 25mg two times per day followed by a one month washout prior to next intervention.</description>
    <arm_group_label>All study participants</arm_group_label>
    <other_name>Viagra, Revatio: sildenafil</other_name>
    <other_name>Cozaar: losartan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>Placebo pill three times per day for 3 months followed by a one month washout prior to next intervention.</description>
    <arm_group_label>All study participants</arm_group_label>
    <other_name>Placebo pill (sugar)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-99

          -  Have not taken any of the study medications in the past 6 weeks

          -  Diagnosed with idiopathic pulmonary fibrosis

        Exclusion Criteria:

          -  FVC&lt;50%, DLco &lt;30% or FEV1/FVC ratio &lt;65%

          -  Greater amount of emphysema than fibrotic change on chest CT scan

          -  Acute myocardial infarction within the past 6 months

          -  Nitrate use

          -  Contraindications, hypersensitivity, or allergic reaction to any study medication

          -  Presence of aortic stenosis

          -  Life-threatening arrhythmia within 1 month of evaluation

          -  Diabetes requiring insulin therapy

          -  Second-degree or third-degree atrioventricular block on electrocardiogram

          -  Echocardiographic evidence of severe pulmonary hypertension (&gt;50mmHg) â€¢ Severe
             terminal illness (survival predicted to be less than 1 year)

          -  Severe congestive heart failure

          -  Renal impairment (creatinine &gt;2.0 mg/dl)

          -  Moderate to severe hepatic impairment

          -  Concurrent treatment with immunosuppressive, cytotoxic, or investigational agents.

          -  Pregnant or Breastfeeding (Women of childbearing age must use effective form of birth
             control or abstinence during study participation)

          -  History of acute exacerbation of IPF

          -  Current enrollment in another investigational protocol

          -  Acute or chronic impairment other than dyspnea that limits the patient's ability to
             perform the six minute walk test

          -  Current drug or alcohol dependence

          -  Initiation of pulmonary rehabilitation within 30 days of enrollment. Subjects
             currently undergoing maintenance pulmonary rehabilitation at study entry will be asked
             to maintain their levels of rehabilitation for the duration of the trial

          -  Treatment of pulmonary hypertension with prostaglandins, endothelin-1 antagonists, or
             any other phosphodiesterase inhibitor within 30 days of enrollment

          -  Addition or discontinuation of calcium channel blockers, digitalis, diuretics or
             vasodilators within 30 days of enrollment. Dosage must be stable for 7 days prior to
             enrollment (except for diuretics)

          -  Listed for lung transplantation

          -  Due to drug interactions, all of the following agents will be prohibited:
             alpha-blockers, endothelin-1 antagonists, and CYP3A4 inhibitors

          -  Resting oxygen saturation of &lt;92% with greater than 6 liters of supplemental oxygen
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alicia K Gerke, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Iowa</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>September 19, 2009</study_first_submitted>
  <study_first_submitted_qc>September 19, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2009</study_first_posted>
  <results_first_submitted>July 13, 2018</results_first_submitted>
  <results_first_submitted_qc>October 10, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">November 13, 2018</results_first_posted>
  <last_update_submitted>October 10, 2018</last_update_submitted>
  <last_update_submitted_qc>October 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Iowa</investigator_affiliation>
    <investigator_full_name>Alicia Gerke</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Losartan</mesh_term>
    <mesh_term>Sildenafil Citrate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>All Study Participants</title>
          <description>Participants will be randomized to take one of the study medications (Sildenafil, Losartan, placebo oral tablet, and Sildenafil and Losartan) at a time. Participants will be randomized to take these medications for 3 months with a washout period of one month before starting the next medication. The order or medications taken is random in order to blind the investigator and participant</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Losartan</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Started Losartan</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Losartan</title>
              <participants_list>
                <participants group_id="P1" count="10">Only 9 were analyzed because only 9 completed all four interventions.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10">Only 9 were analyzed because only 9 completed all four interventions.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Placebo Oral Tablet</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Started Placebo Oral Tablet</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Placebo Oral Tablet</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Sildenafil</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Started Sildenafil</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Sildenafil</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Sildenafil and Losartan</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Started Sildenafil and Losartan</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Sildenafil and Losartan</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Subjects were randomized to complete all four arms in random order. There were nine participants analyzed in the study and all nine of those subjects participated in each arm. The numbers above do not include the 3 withdrawn subjects that did not complete the arms.</population>
      <group_list>
        <group group_id="B1">
          <title>All Study Participants</title>
          <description>Study participants are patients that have been diagnosed with idiopathic pulmonary fibrosis (IPF).</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63" lower_limit="45" upper_limit="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Six Minute Walk Distance in Meters</title>
        <description>Change in 6MWD before and after treatment compared to placebo</description>
        <time_frame>At baseline and three months post each intervention.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sildenafil</title>
            <description>Sildenafil: Sildenafil 20mg three times per day for 3 months</description>
          </group>
          <group group_id="O2">
            <title>Losartan</title>
            <description>Losartan: Losartan 25mg two times a day for 3 months</description>
          </group>
          <group group_id="O3">
            <title>Sildenafil and Losartan</title>
            <description>Sildenafil and Losartan: Sildenafil 20mg three times per day and Losartan 25mg two times per day.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo pill: Placebo pill three times per day for 3 months</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Six Minute Walk Distance in Meters</title>
          <description>Change in 6MWD before and after treatment compared to placebo</description>
          <units>meters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.5" spread="23.1"/>
                    <measurement group_id="O2" value="15.8" spread="24.0"/>
                    <measurement group_id="O3" value="-11.1" spread="12.0"/>
                    <measurement group_id="O4" value="12.1" spread="23.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Forced Vital Capacity (FVC)</title>
        <description>Change in FVC before and after treatment compared to placebo. FVC is a measure of lung size.</description>
        <time_frame>At baseline and three months post each intervention.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sildenafil</title>
            <description>Sildenafil: Sildenafil 20mg three times per day for 3 months</description>
          </group>
          <group group_id="O2">
            <title>Losartan</title>
            <description>Losartan: Losartan 25mg two times a day for 3 months</description>
          </group>
          <group group_id="O3">
            <title>Sildenafil and Losartan</title>
            <description>Sildenafil and Losartan: Sildenafil 20mg three times per day and Losartan 25mg two times per day.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo pill: Placebo pill three times per day for 3 months</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Forced Vital Capacity (FVC)</title>
          <description>Change in FVC before and after treatment compared to placebo. FVC is a measure of lung size.</description>
          <units>liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.04" spread=".13"/>
                    <measurement group_id="O2" value="-0.06" spread="0.13"/>
                    <measurement group_id="O3" value="0.002" spread="0.14"/>
                    <measurement group_id="O4" value="-0.02" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Shortness of Breath (SOB) Score</title>
        <description>Change in symptoms of SOB as determined by St. Georges Respiratory Questionnaire score. This score ranges from 0 to 100 with a higher score indicating more problems breathing.</description>
        <time_frame>At baseline and three months post each intervention.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sildenafil</title>
            <description>Sildenafil: Sildenafil 20mg three times per day for 3 months</description>
          </group>
          <group group_id="O2">
            <title>Losartan</title>
            <description>Losartan: Losartan 25mg two times a day for 3 months</description>
          </group>
          <group group_id="O3">
            <title>Sildenafil and Losartan</title>
            <description>Sildenafil and Losartan: Sildenafil 20mg three times per day and Losartan 25mg two times per day.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo pill: Placebo pill three times per day for 3 months</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Shortness of Breath (SOB) Score</title>
          <description>Change in symptoms of SOB as determined by St. Georges Respiratory Questionnaire score. This score ranges from 0 to 100 with a higher score indicating more problems breathing.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="10.3"/>
                    <measurement group_id="O2" value="1.5" spread="5.7"/>
                    <measurement group_id="O3" value="3.3" spread="11.6"/>
                    <measurement group_id="O4" value="-3.0" spread="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Sildenafil</title>
          <description>Sildenafil: Sildenafil 20mg three times per day for 3 months</description>
        </group>
        <group group_id="E2">
          <title>Losartan</title>
          <description>Losartan: Losartan 25mg two times a day for 3 months</description>
        </group>
        <group group_id="E3">
          <title>Sildenafil and Losartan</title>
          <description>Sildenafil and Losartan: Sildenafil 20mg three times per day and Losartan 25mg two times per day.</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>Placebo pill: Placebo pill three times per day for 3 months</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Idiopathic Pulmonary Fibrosis Exacerbation</sub_title>
                <description>Evaluated and documented idiopathic pulmonary fibrosis exacerbation confirmed by medical records.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastroesophageal Reflux</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <description>Not requiring hospitalization.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <description>Increase or worsening of cough</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="12"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Respiratory infection/viral illness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="9"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <description>Outpatient treatment (no hospitalization)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <description>Low blood pressure</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The trial was terminated early due to funding issues. Therefore, power to find a difference is limited.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Alicia Gerke</name_or_title>
      <organization>University of Iowa</organization>
      <phone>319-356-1616</phone>
      <email>alicia-gerke@uiowa.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

